References
- Doherty G, Katsanos KH, Burisch J, et al. European Crohn’s and colitis organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J Crohn’s Colitis. 2018;12:17–31.
- Biroulet LP, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. J Crohn’s Colitis. 2011;5:477–483.
- Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1324–1329.
- Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–858.